Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

LB Pharmaceuticals Inc Common Stock LBRX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
50/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$33.00
+13.3%

LB Pharmaceuticals Inc Common Stock (LBRX) is a Biotechnology company in the Healthcare sector, currently trading at $29.12. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is LBRX = $33 (+13.3% upside).

Valuation: LBRX trades at a trailing Price-to-Earnings (P/E) of -26 (S&P 500 average ~25).

Net income is $25M (loss), growing at -263.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $301M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 41.44 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $313M.

Analyst outlook: 1 / 1 analysts rate LBRX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 88/100 (Pass), Income ?/100 (Fail).

$33.00
▲ 13.32% Upside
Average Price Target
Based on 1 Wall Street analysts offering 12-month price targets for LB Pharmaceuticals Inc Common Stock, the average price target is $33.00, with a high forecast of $35.00, and a low forecast of $31.00.
Highest Price Target
$35.00
Average Price Target
$33.00
Lowest Price Target
$31.00

LBRX SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 88/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LBRX

✓
VALUE Pass
60/100
LBRX trades at a trailing Price-to-Earnings (P/E) of -26 (S&P 500 average ~25). Forward PEG -16.22 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $33, implying +13.3% from the current price $29. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
LBRX: +0%/yr revenue is, -263.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet LBRX: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 41.44 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
LBRX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
88/100
Analyst outlook: 1 / 1 analysts rate LBRX as buy (100%). Analyst consensus target is $33 (+13.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range13.36-27.55
Volume742.66K
Avg Volume (30D)236.97K
Market Cap$835.01M
Beta (1Y)-5.92
Share Statistics
EPS (TTM)-1.00
Shares Outstanding$25.3M
IPO Date2025-09-11
Employees16
CEOZachary Prensky
Financial Highlights & Ratios
Gross Profit$-321K
EBITDA$-30.08M
Net Income$-25.21M
Operating Income$-30.4M
Total Cash$295.21M
Total Debt$3.57M
Net Debt$-246.6M
Total Assets$312.93M
Price / Earnings (P/E)-29.1
Analyst Forecast
1Y Price Target$33.00
Target High$35.00
Target Low$31.00
Upside+13.3%
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS50180M1080

Price Chart

Track all markets on TradingView
LBRX
LB Pharmaceuticals Inc Common Stock ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
13.36 52WK RANGE 27.55

People Also View

DSGN
DSGN
Design Therapeutics, Inc.
$12.75
+0.87%
 ANNX
ANNX
Annexon, Inc.
$6.35
+9.48%
 SLDB
SLDB
Solid Biosciences Inc.
$8.32
+1.09%
 DBVT
DBVT
DBV Technologies S.A.
$21.25
-1.80%
 AURA
AURA
Aura Biosciences, Inc.
$7.09
+0.07%
 RCKT
RCKT
Rocket Pharmaceuticals, Inc.
$3.88
+6.59%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 AUTL
AUTL
Autolus Therapeutics plc
$1.49
+0.68%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message